Navigation Links
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Date:8/4/2011

our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended March 31, 2011.  The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.Biodel Inc.
(A Development Stage Company)
Condensed Balance Sheets
(in thousands, except share and per share amounts)September 30,June 30,20102011(unaudited)ASSETSCurrent:Cash and cash equivalents$

22,922$

41,999Restricted cash15060Marketable securities, available for sale6,001—Taxes receivable11686Other receivables119Prepaid and other assets365497Total cu
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Biodel to Raise $30 Million Through Registered Direct Offering
3. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
4. Biodel Announces Name Change for Lead Product Candidate
5. Dyadic International Reports 2011 Second Quarter Financial Results
6. Vermillion Reports Results for the Second Quarter 2011
7. ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports
8. Dendreon Reports Second Quarter 2011 Financial Results
9. Cambrex Reports Second Quarter of 2011 Results
10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
11. Gen-Probe Reports Financial Results for the Second Quarter of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Solutions, LLC, Santa Clara, CA, a manufacturer of ... applications, announced the release of TruTorr(TM), a single-use ... containers, in order to prevent overpressure damage, at ... TruTorr system consists of a disposable pressure sensor, ...
... option for millions of Americans with debilitating lung ... (NYSE: AZN ) today announced that ... approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for ... in patients with chronic obstructive pulmonary disease (COPD), ...
... Is Just What Diabetics Have Been Waiting For. The Sleek, Bold ... By Storm. , ... Greenville, SC (PRWEB) February 27, 2009 -- For ... that is both functional and attractive. In recent years, many companies ...
Cached Biology Technology:Finesse Announces TruTorr(TM) Single-Use Pressure Sensor 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6Home Delivery Medical Offers New Glucose Meter With State-Of-The-Art Technology 2Home Delivery Medical Offers New Glucose Meter With State-Of-The-Art Technology 3
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... trope that the likelihood of an accurate group decision ... hold up when a collective faces a variety of ... Instead, Princeton University researchers report that smaller groups actually ... may become excessively focused on only certain pieces of ... what is known about collective intelligence, or the "wisdom ...
(Date:4/23/2014)... a signing ceremony in Buenos Aires yesterday, Argentina ... an associate member state. The move strengthens the ... science communities. It grants Argentinian scientists access to ... beneficial collaborations. , "Ever since its inception, fostering ... have been at the core of EMBL,s mission," ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... OTO EXPO of the American Academy of Otolaryngology Head ... nose, and throat doctors in the world, will convene September ... scientific research sessions, 594 posters, and several hundred instruction course ... for journalists from around the world to cover breaking science ...
... 2010 - Eurofins MWG Operon, an expert in next generation ... GS Junior. The GS Junior is the optimum system for ... one eighth of the capacity of a GS FLX Titanium ... run. As a consequence, the GS Junior adds a higher ...
... This release is available in French ... high electrical conductivity that promise to revolutionize a wide range ... A team of McGill University researchers have now reported ... along one single conductive polymer molecule at a time, a ...
Cached Biology News:2010 AAO-HNSF miniseminars: Tuesday, Sept. 28, 2010 22010 AAO-HNSF miniseminars: Tuesday, Sept. 28, 2010 3Striding towards a new dawn for electronics 2